Dr Reddy Laboratories : . Reddy's launches in-house palbociclib (PRIMCYV®) to widen access to high-quality breast cancer ug - Form 6-K

(marketscreener.com) Dr. Reddy's launches in-house palbociclib to widen access to high-quality breast cancer drug · First-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic...https://www.marketscreener.com/quote/stock/DR-REDDY-S-LABORATORIES-6492671/news/Dr-Reddy-Laboratories-Reddy-s-launches-in-house-palbociclib-PRIMCYV-to-widen-access-to-high-q-42728284/?utm_medium=RSS&utm_content=20230113